Investors & Media

Dec 4, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Dec 4, 2021 / Dec 4, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

11/10/21

BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
- Announced positive findings from the Phase 2b SOOTHE trial administrative interim analysis, with at least one dose of BLU-5937 meeting the threshold for a high probability of clinical efficacy - - Phase 2b SOOTHE and Phase 2a BLUEPRINT trials are fully enrolled, with topline results expected in...
Read More
11/10/21

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec --(BUSINESS WIRE)--Nov. 10, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related...
Read More
11/1/21

BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
- Live webcast to be held on November 15 th at 12:00 p.m. EST – LAVAL, Quebec --(BUSINESS WIRE)--Nov. 1, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory...
Read More